The Value of Phenotypic Precision Medicine in Prostate Cancer.
The Value of Phenotypic Precision Medicine in Prostate Cancer.
复制标题
DOI：
10.1093/oncolo/oyac198
复制
发表时间：
2023-02-08
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
前列腺癌是男性中最常见的癌症，也是癌症相关死亡的第二大原因。对于发生转移性疾病的患者，基于组织和循环肿瘤的分子和基因组生物标志物已成为通过应用精准医学改善结果的一种手段。然而，这种益处仅限于少数患者。进一步表征晚期前列腺癌生物学的另一种方法是通过使用表型精准医学，或识别和靶向个体患者癌症的表型特征。在这篇综述文章中，我们将讨论基因组和表型精准医学在前列腺癌中的背景，潜在的临床益处和局限性。我们还将强调基于图像的表型医学的出现如何可能导致晚期前列腺癌疾病负担的更大表征和患者的更个性化的治疗方法。本综述报告了前列腺癌基因组和表型精准医学的背景、潜在临床益处和局限性，强调了基于图像的表型医学的出现如何可能导致晚期前列腺癌疾病负担的更大表征和患者更个性化的治疗方法。
Prostate cancer is the most common cancer among men and the second leading cause of cancer-related death. For patients who develop metastatic disease, tissue-based and circulating-tumor–based molecular and genomic biomarkers have emerged as a means of improving outcomes through the application of precision medicine. However, the benefit is limited to a minority of patients. An additional approach to further characterize the biology of advanced prostate cancer is through the use of phenotypic precision medicine, or the identification and targeting of phenotypic features of an individual patient’s cancer. In this review article, we will discuss the background, potential clinical benefits, and limitations of genomic and phenotypic precision medicine in prostate cancer. We will also highlight how the emergence of image-based phenotypic medicine may lead to greater characterization of advanced prostate cancer disease burden and more individualized treatment approaches in patients. This review reports the background, potential clinical benefits, and limitations of genomic and phenotypic precision medicine in prostate cancer, highlighting how the emergence of image-based phenotypic medicine may lead to greater characterization of advanced prostate cancer disease burden and more individualized treatment approaches in patients.
登录
查看更多内容
影响因子：
82.9
作者：
Beltran H;Prandi D;Mosquera JM;Benelli M;Puca L;Cyrta J;Marotz C;Giannopoulou E;Chakravarthi BV;Varambally S;Tomlins SA;Nanus DM;Tagawa ST;Van Allen EM;Elemento O;Sboner A;Garraway LA;Rubin MA;Demichelis F
通讯作者：
Demichelis F
DOI：
10.1016/j.juro.2016.09.117
发表时间：
2017-03
期刊：
The Journal of urology
影响因子：
--
作者：
Bach-Gansmo T;Nanni C;Nieh PT;Zanoni L;Bogsrud TV;Sletten H;Korsan KA;Kieboom J;Tade FI;Odewole O;Chau A;Ward P;Goodman MM;Fanti S;Schuster DM;Willoch F
通讯作者：
Willoch F
影响因子：
4.6
作者：
Abida W;Armenia J;Gopalan A;Brennan R;Walsh M;Barron D;Danila D;Rathkopf D;Morris M;Slovin S;McLaughlin B;Curtis K;Hyman DM;Durack JC;Solomon SB;Arcila ME;Zehir A;Syed A;Gao J;Chakravarty D;Vargas HA;Robson ME;Joseph V;Offit K;Donoghue MTA;Abeshouse AA;Kundra R;Heins ZJ;Penson AV;Harris C;Taylor BS;Ladanyi M;Mandelker D;Zhang L;Reuter VE;Kantoff PW;Solit DB;Berger MF;Sawyers CL;Schultz N;Scher HI
通讯作者：
Scher HI
影响因子：
51.1
作者：
Gafita, Andrei;Calais, Jeremie;Eiber, Matthias
通讯作者：
Eiber, Matthias
DOI：
10.1016/j.juro.2018.08.050
发表时间：
2019-03
期刊：
The Journal of urology
影响因子：
--
作者：
Andriole GL;Kostakoglu L;Chau A;Duan F;Mahmood U;Mankoff DA;Schuster DM;Siegel BA;LOCATE Study Group
通讯作者：
LOCATE Study Group